There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.